Nestlé Health Science’s most exposed flank is medical-nutrition supply, the ground on which Danone (Nutricia) and Abbott Nutrition compete for hospital and pharmacy accounts, and where a withdrawal costs more than anywhere else. Its consumer side, built by acquiring VITAL PROTEINS, SOLGAR, BOOST and related brands, still competes with Herbalife and GNC for retail shelf space.

The withdrawal of enteral products in 2023 shows what that exposure costs: several products were discontinued on cited supply-chain issues and increased demand, with customers routed to alternative products through their Nestlé representative or distributor. Each formula dropped gives up a hospital or pharmacy listing to a competitor that can still fill the order.

The category’s move toward weight management and gut health favors a business that already sells both clinical nutrition and everyday supplements, which is where Nestlé Health Science sits relative to named alternatives Danone (Nutricia), Abbott Nutrition, Herbalife and GNC. Demand for nutrition that supports medical treatment and weight management strengthens that position more than it erodes it.

Two moves put the company directly on the demand shifts reshaping the category: a GLP-1 nutrition support platform launched in 2024 and a longitudinal lifestyle and gut-health study announced in January 2026. Consolidation is also reshaping the business from inside Nestlé, where a 1 April 2026 merger with Nestlé Nutrition concentrated clinical and consumer nutrition lines in one unit.